We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: 心血管医学
MedXY News
EnglishTag

心血管医学

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical Practice
CardiologyGDMThealth equity

Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical Practice

By MedXY|Apr 5, 2026

A large retrospective study of 52,850 veterans reveals that just 21.2% achieve guideline-directed quadruple therapy for HFrEF, with a median time of 197 days. Socioeconomic barriers, including prescription copays, emerge as critical modifia

Bridging the Evidence Gap: African Representation in Global Randomized Controlled Trials (2019–2024)
Medical Newsclinical trialsGlobal Health Equity

Bridging the Evidence Gap: African Representation in Global Randomized Controlled Trials (2019–2024)

By MedXY|Mar 20, 2026

This systematic review analyzes the profound underrepresentation of African populations in high-impact clinical trials, revealing a stark disparity in cardiovascular and general medical research that limits the global applicability of evide

VOYAGER-PAD Insight: Prior Revascularization History Mandates More Aggressive Antithrombotic Therapy
CardiologyPeripheral Artery DiseaseRevascularization

VOYAGER-PAD Insight: Prior Revascularization History Mandates More Aggressive Antithrombotic Therapy

By MedXY|Mar 2, 2026

A VOYAGER-PAD sub-analysis reveals that patients with prior limb revascularization are at significantly higher risk for adverse events but derive a greater relative benefit from low-dose rivaroxaban plus aspirin.

Metformin Fails to Improve Walking Performance in Peripheral Artery Disease: Results of the PERMET Randomized Trial
Cardiologyclinical trialsmetformin

Metformin Fails to Improve Walking Performance in Peripheral Artery Disease: Results of the PERMET Randomized Trial

By MedXY|Feb 23, 2026

The PERMET randomized clinical trial found that metformin did not improve the 6-minute walk distance or secondary walking outcomes in patients with peripheral artery disease without diabetes, suggesting no benefit for functional impairment

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities